This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuchs, P. C.
Right arrow Articles by Brown, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuchs, P. C.
Right arrow Articles by Brown, S. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1999, p. 2996-2997, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Activities of SCH27899 Alone and in Combination with 17 Other Antimicrobial Agents

Peter C. Fuchs,* Arthur L. Barry, and Steven D. Brown

Clinical Microbiology Institute, Wilsonville, Oregon 97070

Received 14 June 1999/Returned for modification 31 July 1999/Accepted 13 September 1999

SCH27899, an everninomicin antibiotic, was tested for its in vitro activity against 718 bacterial isolates representing 27 species. The Enterobacteriaceae and nonenteric gram-negative bacilli were resistant to >= 8.0 µg/ml, but all others were inhibited by <= 1.0 µg/ml. When tested in combination with 17 other antimicrobial agents against 110 strains, SCH27899 demonstrated no significant antagonism or synergy. Consequently, combination therapy is not contraindicated.

* Corresponding author. Mailing address: Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, OR 97070. Phone: (503) 682-3232. Fax: (503) 682-4548. E-mail: cmi{at}hevanet.com.

Antimicrobial Agents and Chemotherapy, December 1999, p. 2996-2997, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Butaye, P., Devriese, L. A., Haesebrouck, F. (2003). Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria. Clin. Microbiol. Rev. 16: 175-188 [Abstract] [Full Text]  
  • Weitnauer, G., Gaisser, S., Kellenberger, L., Leadlay, P. F., Bechthold, A. (2002). Analysis of a C-methyltransferase gene (aviG1) involved in avilamycin biosynthesis in Streptomyces viridochromogenes Tu57 and complementation of a Saccharopolyspora erythraea eryBIII mutant by aviG1. Microbiology 148: 373-379 [Abstract] [Full Text]  
  • Hallgren, A., Abednazari, H., Ekdahl, C., Hanberger, H., Nilsson, M., Samuelsson, A., Svensson, E., Nilsson, L. E., Swedish ICU Study Group, t. (2001). Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems. J Antimicrob Chemother 48: 53-62 [Abstract] [Full Text]  
  • Weitnauer, G., Gaisser, S., Trefzer, A., Stockert, S., Westrich, L., Quiros, L. M., Mendez, C., Salas, J. A., Bechthold, A. (2001). An ATP-Binding Cassette Transporter and Two rRNA Methyltransferases Are Involved in Resistance to Avilamycin in the Producer Organism Streptomyces viridochromogenes Tu57. Antimicrob. Agents Chemother. 45: 690-695 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»